


CLAIMS

What is claimed is:

1. Use of a compound represented by:




- 5 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a tenosynovial giant cell tumor in a patient in need thereof, wherein the compound is to be orally administered to the patient.
2. The use of claim 1, wherein the tenosynovial giant cell tumor is diffuse-type tenosynovial giant cell tumor.
- 10 3. The use of claim 1, wherein the tumor is benign.
4. The use of any one of claims 1-3, wherein 2 mg to 60 mg of the compound is to be administered to the patient daily, once a week, twice a week, or three times a week.
5. The use of any one of claims 1-3, wherein 10 to 90 mg of the compound is to be administered to the patient daily, once a week, twice a week, or three times a week.
- 15 6. The use of any one of claims 1-3, wherein
a loading dose of the compound is to be administered daily for a first time period;
and
a maintenance dose of the compound is to be administered daily, twice weekly, or three times a week for a second time period.
- 20 7. The use of claim 6, wherein the loading dose is 10 to 80mg/day.
8. The use of claim 6 or 7 wherein the loading dose is 20 to 60mg/day.

9. The use of any one of claims 6-8, wherein the loading dose is 20mg, 30mg/day, 40mg/day, 50mg/day or 60mg/day.
10. The use of any one of claims 6-9, wherein the maintenance dose is 2mg to 60mg.
11. The use of any one of claims 6-10, wherein the maintenance dose is 2mg, 10 mg, 20mg, 25mg, 30mg, 40mg or 50mg each administered twice or three times a week.
12. The use of any one of claims 6-11, wherein the first time period is one or two weeks.
13. The use of any one of claims 6-12, wherein the first time period is 4 days, 5 days, 6 days, or 10 days.
14. The use of any one of claims 6-13, wherein the second time period is one month to two months, three months or more.
15. The use of any one of claims 6-14, wherein the second time period is one month to nine months or more.
16. The use of any one of claims 6-14, wherein an additional loading dose is to be further administered during a third time period.
17. The use of claim 16, wherein an additional maintenance dose is to be further administered during a fourth time period.
18. The use of claim 15 or 16, wherein the third and/or fourth time period occurs after the first and second time period.
19. The use of any one of claims 1-17, wherein after 1 month or more of administration, the patient has an improved tumor response as measured by CT, MRI and/or RECIST.
20. The use of any one of claims 1-18, wherein the compound is to be administered for 1 month or more, and after 1 month or more of administration, the patient has an improved range of motion.
21. The use of any one of claims 1-19, wherein the compound is to be administered for 1 month or more, and after 1 month or more of administration, the patient has reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.

22. The use of any one of claims 6-21, wherein the compound is to be administered, and wherein the size of the tenosynovial giant cell tumor decreases to 90% to 10% of its size prior to administering.

23. Use of a compound represented by:



5

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a tenosynovial giant cell tumor in a patient in need thereof, wherein 2 mg to 50 mg of the compound is to be orally administered to the patient twice weekly.

24. The use of claim 23, wherein 5 mg to 30 mg of the compound is to be administered to the patient twice weekly.

10

25. The use of claim 23 or 24, wherein 20 mg of the compound is to be administered to the patient twice weekly.


26. The use of claim 23 or 24, wherein 14 mg of the compound is to be administered to the patient twice weekly.

27. The use of any one of claims 23-26, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

15

28. The use of any one of claims 23-27, wherein the tumor is benign.

29. Use of a compound represented by:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a tenosynovial giant cell tumor in a patient in need thereof, wherein 30 mg of the compound is to be orally administered to the patient twice weekly.

30. The use of claim 29, wherein the tumor is benign.
- 5 31. The use of claim 29 or 30, wherein the compound is to be administered to the patient twice weekly for at least 6 months.
32. The use of claim 29 or 30, wherein the compound is to be administered to the patient twice weekly for 1 year.
- 10 33. The use of any one of claims 1-32, wherein the tenosynovial giant cell tumor is additionally to be surgically treated in the patient.
34. The use of claim 33, wherein the compound is to be administered to the patient as an adjuvant after surgically treating the tenosynovial giant cell tumor in the patient.
- 15 35. The use of claim 33, wherein the compound is to be administered to the patient as a neo-adjuvant prior to surgically treating the tenosynovial giant cell tumor in the patient.
- 20 36. The use of any one of claims 1-35, wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.
37. The use of claim 36, wherein the size of the tenosynovial giant cell tumor decreases to 90% to 10% of its size prior to administering.
38. The use of claim 29 or 30, wherein the compound is to be administered to the patient twice weekly for at least 3 months.
- 25 39. The use of claim 29 or 30, wherein the compound is to be administered to the patient twice weekly for at least 1 month.